Related by context. Frequent words. (Click for all words.) 76 Complete Response letter 74 Complete Response Letter 68 FDA approvable letter 65 Approvable Letter 62 Citizen Petition 61 Warning Letter 61 approvable letter 60 Act PDUFA date 60 Complete Response 59 Staff Determination Letter 59 Nasdaq Hearings Panel 58 European Medicines Evaluation 58 PDUFA date 58 IMPAX Laboratories Inc. 57 supplemental Biologics License Application 57 Inc. Nasdaq HGSI 56 Company Nasdaq PRGO 56 FDA Accepts 56 submitted Biologics License 56 Inc. Nasdaq ARNA 55 Oncologic Drugs Advisory 55 Inc. NASDAQ ALKS 55 NASDAQ Listing 54 submitted Marketing Authorization 54 Inc. NYSE AGN 54 Palatin Technologies Inc. 54 Marketing Authorization Application 54 Staff Deficiency Letter 54 Metabolic Drugs Advisory 54 Scientific Advice 54 Marketing Authorization Application MAA 53 Ligand Pharmaceuticals Incorporated 53 NASDAQ ARIA 53 SHPGY 53 Positive Opinion 53 QNEXA 53 Corporation Nasdaq GENZ 53 Protalix BioTherapeutics Inc. 52 Marketing Authorization 52 IPXL 52 approvability 52 editor letters@smdailyjournal.com 52 Nymox Pharmaceutical Corporation 52 sBLA 52 Drug Application 52 sNDA 52 BioDelivery Sciences 52 Listing Qualifications Panel 52 NASDAQ Listing Qualifications 52 Biologics License Application BLA 51 Severe Weather Statement 51 CHMP 51 Inc. Nasdaq EXEL 51 Company NASDAQ MDCO 51 DISCLOSURE NOTICE 51 Actelion Ltd 51 NYSE MYL 51 Nasdaq VRTX 51 Telavancin 51 ZIOPHARM Oncology 51 Biologics License Application 51 Investigational Device Exemption 51 Pirfenidone 51 Corporation NASDAQ GENZ 50 Drug Administration FDA 50 Nasdaq ITMN 50 Anika Therapeutics Inc. 50 Q2 Loss Narrows 50 Panzem R 50 FastMarkets Ltd 50 Staff Determination 50 Horizant 50 Full Prescribing Information 50 Afrezza 50 Paragraph IV 50 Downtrend Alert 50 Shareholder Update 50 Neupro ® 50 EPIX Pharmaceuticals 50 Hold Fourth Quarter 50 Altus Pharmaceuticals Inc. 49 DYAX 49 alogliptin 49 Dynavax Technologies Corporation 49 Clinical Trial Application 49 Boxed Warning 49 Generic Version 49 Company Prospectus dated 49 Oscient Pharmaceuticals 49 CHMP opinion 49 Listing Qualifications 49 XM Radio Investor Relations 49 DepoMed 49 BLA submission 49 Inc. Nasdaq NVAX 49 Swissmedic 49 Medicinal Products 49 Orphan Drug designation 49 Gleaner editorial 49 earthtalk@emagazine.com 49 Webcast Annual Meeting